FDA Advisory Committee Reviews Advanced Melanoma Treatment

An FDA advisory committee is convening today to review vusolimogene oderparepvec, a proposed therapy for adult patients with advanced melanoma previously treated with anti–PD-1 regimens. The committee's recommendations will guide the FDA's decision on this Biologics License Application, potentially offering a new treatment option for a challenging cancer. This could significantly impact patient care.